Persistence of the neutralizing antibody response one year after a single injection of a new Yellow fever vaccine in adults
Introduction: Yellow fever (YF) remains a major global health threat, complicated by climate change, vector expansion, and insufficient health system infrastructure in endemic regions. Recent shortages of licensed vaccines during regional outbreaks underscore the need for next-generation YF vaccines...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | International Journal of Infectious Diseases |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971224005228 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850184132424892416 |
|---|---|
| author | Dr Emmanuel Feroldi Prof Mark J Mulligan Dr Kawsar Talaat Dr Chen Sabrina Tan Dr Kristopher Paolino Prof Srilatha Edupuganti Prof Matthew H Collins Prof Sarah L George Dr Matthew Davis Dr Brandon Essink Dr James Peterson Dr David Fried Dr Natalia Rodriguez Valero Prof Michael Ramharter Prof Odile Launay Prof Anu Kantele Prof Terapong Tantawichien Prof Jenny Guek-Hong Low Ms Sandrine Orlando Ms Pascale Davaux Ms Tifany Machabert Ms Marine Dufournet Mr Louis Devlin Dr Carina Frago |
| author_facet | Dr Emmanuel Feroldi Prof Mark J Mulligan Dr Kawsar Talaat Dr Chen Sabrina Tan Dr Kristopher Paolino Prof Srilatha Edupuganti Prof Matthew H Collins Prof Sarah L George Dr Matthew Davis Dr Brandon Essink Dr James Peterson Dr David Fried Dr Natalia Rodriguez Valero Prof Michael Ramharter Prof Odile Launay Prof Anu Kantele Prof Terapong Tantawichien Prof Jenny Guek-Hong Low Ms Sandrine Orlando Ms Pascale Davaux Ms Tifany Machabert Ms Marine Dufournet Mr Louis Devlin Dr Carina Frago |
| author_sort | Dr Emmanuel Feroldi |
| collection | DOAJ |
| description | Introduction: Yellow fever (YF) remains a major global health threat, complicated by climate change, vector expansion, and insufficient health system infrastructure in endemic regions. Recent shortages of licensed vaccines during regional outbreaks underscore the need for next-generation YF vaccines that retain safety and effectiveness standards while enhancing manufacturing efficiency. Grown in serum-free Vero cells, vYF is a live-attenuated YF vaccine developed to ensure a sustainable and robust global supply. Methods: In two ongoing Phase II randomized, observer-blind, active-controlled, non-inferiority multicenter clinical trials of vYF in 18-60-year-old adults in the US (vs. YF-VAX – VYF02 study) or in Europe and Asia (vs. Stamaril – VYF03 study), the neutralizing antibody (NAb) responses are being measured by a YF microneutralization assay on day 29 (D29), month 6 (M6), and then annually from year 1 (Y1) until Y5. Seroprotection is defined as NAb titers ≥ 10 (1/dil). Interim analyses conducted one-month post-vaccination demonstrated that the vYF immune response was non-inferior to YF-VAX or Stamaril. Here, we report the immunogenicity up to Y1.Adults were randomized 2:1 to receive one dose of vYF or YF active control: 568 in the US (VYF02) and 690 in Europe and Asia (VYF03). Results: Twenty-eight days after a vYF dose administration, over 99% of YF-naive participants in the US, and over 98% in the EU and over 95% in Asia were seroprotected.YF-naive recipients (FAS) exhibited D29 post-vaccination geometric mean titers (GMT) well above the seroprotective threshold: 2654, 1/dil, in the US; 2508, 1/dil, in EU; 1374, 1/dil, in Asia. As expected, GMTs waned after D29 but more than 97% of participants in the US, over 98% in Europe and more than 94% in Asia maintained titers above the threshold of protection at Y1, with GMTs of 401, 1/dil, in the US; 469, 1/dil, in EU; and 205, 1/dil, in Asia. Discussion: Overall, 94% or more of YF-naive adults in US, EU and Asia were seroprotected 28 days after receiving vYF and remained seroprotected at Y1. Seroprotection rates and GMT values following administration of the control vaccines (YF-VAX or Stamaril) were in similar ranges at all evaluated timepoints. Despite lower NAb titers observed in Asia from D29, GMT values remain well above the threshold considered for protection in all regions. Conclusion: Immunogenicity of vYF is non-inferior to YF-VAX and Stamaril, inducing seroprotective NAb responses in 18 to 60-year-old vaccinees to 1-year post-vaccination. Reduced NAb titers in Asia relative to the US and Europe did not diminish rates of seroprotection. These results are encouraging for addressing unmet public health needs during YF outbreaks. |
| format | Article |
| id | doaj-art-7416b77004a040bf89fa9e982dccef6c |
| institution | OA Journals |
| issn | 1201-9712 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj-art-7416b77004a040bf89fa9e982dccef6c2025-08-20T02:17:08ZengElsevierInternational Journal of Infectious Diseases1201-97122025-03-0115210744710.1016/j.ijid.2024.107447Persistence of the neutralizing antibody response one year after a single injection of a new Yellow fever vaccine in adultsDr Emmanuel Feroldi0Prof Mark J Mulligan1Dr Kawsar Talaat2Dr Chen Sabrina Tan3Dr Kristopher Paolino4Prof Srilatha Edupuganti5Prof Matthew H Collins6Prof Sarah L George7Dr Matthew Davis8Dr Brandon Essink9Dr James Peterson10Dr David Fried11Dr Natalia Rodriguez Valero12Prof Michael Ramharter13Prof Odile Launay14Prof Anu Kantele15Prof Terapong Tantawichien16Prof Jenny Guek-Hong Low17Ms Sandrine Orlando18Ms Pascale Davaux19Ms Tifany Machabert20Ms Marine Dufournet21Mr Louis Devlin22Dr Carina Frago23Sanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceSanofi, Lyon, FranceIntroduction: Yellow fever (YF) remains a major global health threat, complicated by climate change, vector expansion, and insufficient health system infrastructure in endemic regions. Recent shortages of licensed vaccines during regional outbreaks underscore the need for next-generation YF vaccines that retain safety and effectiveness standards while enhancing manufacturing efficiency. Grown in serum-free Vero cells, vYF is a live-attenuated YF vaccine developed to ensure a sustainable and robust global supply. Methods: In two ongoing Phase II randomized, observer-blind, active-controlled, non-inferiority multicenter clinical trials of vYF in 18-60-year-old adults in the US (vs. YF-VAX – VYF02 study) or in Europe and Asia (vs. Stamaril – VYF03 study), the neutralizing antibody (NAb) responses are being measured by a YF microneutralization assay on day 29 (D29), month 6 (M6), and then annually from year 1 (Y1) until Y5. Seroprotection is defined as NAb titers ≥ 10 (1/dil). Interim analyses conducted one-month post-vaccination demonstrated that the vYF immune response was non-inferior to YF-VAX or Stamaril. Here, we report the immunogenicity up to Y1.Adults were randomized 2:1 to receive one dose of vYF or YF active control: 568 in the US (VYF02) and 690 in Europe and Asia (VYF03). Results: Twenty-eight days after a vYF dose administration, over 99% of YF-naive participants in the US, and over 98% in the EU and over 95% in Asia were seroprotected.YF-naive recipients (FAS) exhibited D29 post-vaccination geometric mean titers (GMT) well above the seroprotective threshold: 2654, 1/dil, in the US; 2508, 1/dil, in EU; 1374, 1/dil, in Asia. As expected, GMTs waned after D29 but more than 97% of participants in the US, over 98% in Europe and more than 94% in Asia maintained titers above the threshold of protection at Y1, with GMTs of 401, 1/dil, in the US; 469, 1/dil, in EU; and 205, 1/dil, in Asia. Discussion: Overall, 94% or more of YF-naive adults in US, EU and Asia were seroprotected 28 days after receiving vYF and remained seroprotected at Y1. Seroprotection rates and GMT values following administration of the control vaccines (YF-VAX or Stamaril) were in similar ranges at all evaluated timepoints. Despite lower NAb titers observed in Asia from D29, GMT values remain well above the threshold considered for protection in all regions. Conclusion: Immunogenicity of vYF is non-inferior to YF-VAX and Stamaril, inducing seroprotective NAb responses in 18 to 60-year-old vaccinees to 1-year post-vaccination. Reduced NAb titers in Asia relative to the US and Europe did not diminish rates of seroprotection. These results are encouraging for addressing unmet public health needs during YF outbreaks.http://www.sciencedirect.com/science/article/pii/S1201971224005228 |
| spellingShingle | Dr Emmanuel Feroldi Prof Mark J Mulligan Dr Kawsar Talaat Dr Chen Sabrina Tan Dr Kristopher Paolino Prof Srilatha Edupuganti Prof Matthew H Collins Prof Sarah L George Dr Matthew Davis Dr Brandon Essink Dr James Peterson Dr David Fried Dr Natalia Rodriguez Valero Prof Michael Ramharter Prof Odile Launay Prof Anu Kantele Prof Terapong Tantawichien Prof Jenny Guek-Hong Low Ms Sandrine Orlando Ms Pascale Davaux Ms Tifany Machabert Ms Marine Dufournet Mr Louis Devlin Dr Carina Frago Persistence of the neutralizing antibody response one year after a single injection of a new Yellow fever vaccine in adults International Journal of Infectious Diseases |
| title | Persistence of the neutralizing antibody response one year after a single injection of a new Yellow fever vaccine in adults |
| title_full | Persistence of the neutralizing antibody response one year after a single injection of a new Yellow fever vaccine in adults |
| title_fullStr | Persistence of the neutralizing antibody response one year after a single injection of a new Yellow fever vaccine in adults |
| title_full_unstemmed | Persistence of the neutralizing antibody response one year after a single injection of a new Yellow fever vaccine in adults |
| title_short | Persistence of the neutralizing antibody response one year after a single injection of a new Yellow fever vaccine in adults |
| title_sort | persistence of the neutralizing antibody response one year after a single injection of a new yellow fever vaccine in adults |
| url | http://www.sciencedirect.com/science/article/pii/S1201971224005228 |
| work_keys_str_mv | AT dremmanuelferoldi persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT profmarkjmulligan persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT drkawsartalaat persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT drchensabrinatan persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT drkristopherpaolino persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT profsrilathaedupuganti persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT profmatthewhcollins persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT profsarahlgeorge persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT drmatthewdavis persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT drbrandonessink persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT drjamespeterson persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT drdavidfried persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT drnataliarodriguezvalero persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT profmichaelramharter persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT profodilelaunay persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT profanukantele persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT profterapongtantawichien persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT profjennyguekhonglow persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT mssandrineorlando persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT mspascaledavaux persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT mstifanymachabert persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT msmarinedufournet persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT mrlouisdevlin persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults AT drcarinafrago persistenceoftheneutralizingantibodyresponseoneyearafterasingleinjectionofanewyellowfevervaccineinadults |